GlaxoSmithKline Gets FDA Priority Review of Belantamab Mafodotin in Multiple Myeloma
21 Janeiro 2020 - 12:53PM
Dow Jones News
By Colin Kellaher
GlaxoSmithKline PLC (GSK.LN, GSK) on Tuesday said the U.S. Food
and Drug Administration granted priority review to its biologics
license application for belantamab mafodotin in a form of the blood
cancer multiple myeloma.
The U.K. drug maker said the application covers the treatment of
patients with relapsed or refractory multiple myeloma whose prior
therapy included an immunomodulatory agent, a proteasome inhibitor
and an anti-CD38 antibody.
The FDA grants priority review to medicines that have the
potential to provide significant improvements in the treatment of a
serious disease, and the designation shortens the review
period.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 21, 2020 10:38 ET (15:38 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Gsk (LSE:GSK)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
